Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …

The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Takayasu arteritis (TAK) refractory to conventional disease-modifying anti-rheumatic drugs
(DMARDs) is commonly treated with biologic DMARDs such as tocilizumab or tumor …

This review overviews the challenges in the assessment of disease activity, damage, and
therapy of Takayasu arteritis (TAK). Recently developed disease activity scores for TAK are …

Purpose We evaluated T helper lymphocyte profile, including novel Th17 subsets Th17. 1
(secrete IFN-γ, associate with corticosteroid resistance) and PD1+ Th17 (secrete TGF-β1 …

We evaluated clinical response, normalization of inflammatory markers, angiographic
stabilization (primary outcomes), relapses and adverse events (secondary outcomes) in …

Arterial wall damage in Takayasu arteritis (TAK) can progress despite immunosuppressive
therapy. Vascular fibrosis is more prominent in TAK than in giant cell arteritis (GCA). The …

Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of
involved arteries is difficult to access except during open surgical procedures. Assessment …

Takayasu arteritis (TAK) could cause a stroke or transient ischemic attack (TIA) in young
individuals due to inflammatory vascular occlusion or intracerebral hemorrhage. We …

Corticosteroid-sparing disease-modifying anti-rheumatic drugs are an area of active
exploration in large vessel vasculitis (LVV), ie, Takayasu arteritis (TAK) and Giant Cell …